Wu Jindao, Ding Wenzhou, Han Guoyong, You Wei, Gao Wen, Shen Hongbing, Tang Jinhai, Tang Qiyun, Wang Xuehao
Key Laboratory of Liver Transplantation, Chinese Academy of Medical Sciences, Hepatobiliary Center, Department of Breast Surgery, Department of Oncology, Department of Geriatric Digestion, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.
Biomater Sci. 2021 Jan 5;9(1):116-123. doi: 10.1039/d0bm00971g.
Nanomedicines generally suffer from poor accumulation in tumor cells, low anti-tumor efficacy, and drug resistance. In order to address these problems, we introduced a novel nanomedicine based on dual anti-cancer drugs, which showed good cell nuclear accumulation properties. The novel nanomedicine consisted of three components: (1) dual anti-cancer drugs, 10-hydroxycamptothecin (HCPT) and chlorambucil (CRB), whose targets are located in the cell nucleus, (2) a nuclear localizing dodecapeptide, PMI peptide (TSFAEYWNLLSP), which could activate p53 by binding with MDM2 and MDMX located in the cell nucleus, and (3) an efficient self-assembling tripeptide FFY. Our nanomedicine exhibited enhanced cellular uptake and nuclear accumulation properties, thus achieving an excellent anti-cancer capacity both in vitro and in vivo. Our study will provide an inspiration for the development of novel multifunctional nanomaterials for cancer diagnosis and therapy.
